Ligand Pharmaceuticals Inc. (LGND) — Analysis Summary
Ligand Pharmaceuticals Inc. (LGND) has a market cap of $6.20B with year-over-year revenue growth of +60.4%. Net margin stands at 46.4%. The stock trades at a P/E ratio of 31.4.
Key Takeaways
- Revenue changed +60.4% year-over-year
- Net margin of 46.4%
- P/E ratio of 31.4
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, LGND posted revenue growth of +60.4% and trades at a P/E of 31.4.
Ligand Pharmaceuticals Inc. (LGND)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 8.8x — highly leveraged, potential refinancing risk
Operating margin (32.6%) exceeds gross margin (0.0%) — check for other operating income or data classification issues
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
47
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Annual Dividend/Share
N/A
Dividend Yield
N/A
Dividend History
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.